Literature DB >> 29658257

[Ningmitai Capsules combined with doxycycline hydrochloride for Ureaplasma urealyticumpositive chronic prostatitis].

Li-Hua Li1, Xun-Bin Huang1, Hui-Ping Zhang1, Dun-Zhen Xiao1, Jing-Song Chai1, Zhen Ye1.   

Abstract

OBJECTIVE: To investigate the effects of Ningmitai Capsules (NMT) combined with doxycycline hydrochloride (DH) on chronic prostatitis induced by Ureaplasma urealyticum (Uu).
METHODS: This randomized controlled trial included 240 male patients with Uupositive chronic prostatitis, treated orally with NMT at 4 capsules tid (n= 35), DH at 100 mg bid (n = 78), and NMT+DH at the corresponding doses (n = 127), respectively, all for 2 successive weeks. At 1 week after drug withdrawl, we conducted routine urine analysis, EPS examination, and drug sensitivity test of the cultured Uu.
RESULTS: The positivetonegative rate of Uu was significantly higher in the NMT+DH group than in the NMT and DH groups (89.0% [113/127] vs 54.3% [19/35] and 71.8% [56/78], P< 0.05), so were the cure rate (25.2% vs 20.0% and 20.5%, P< 0.05) and total effectiveness rate (89.0% vs 54.3% and 71.8%, P< 0.05).
CONCLUSIONS: The combination of Ningmitai Capsules and doxycycline hydrochloride is more effective than either Ningmitai Capsules or doxycycline hydrochloride used alone in the treatment of Uupositive chronic prostatitis.

Entities:  

Keywords:  Ningmitai Capsules; Ureaplasma urealyticum; chronic prostatitis; doxycycline hydrochloride; drug combination

Mesh:

Substances:

Year:  2017        PMID: 29658257

Source DB:  PubMed          Journal:  Zhonghua Nan Ke Xue        ISSN: 1009-3591


  1 in total

1.  Ningmitai capsule promotes calculi expulsion after RIRS for 10-20-mm upper urinary stones: a multicenter, prospective, randomized controlled trial.

Authors:  Ruofan Wang; Qingdong Qiao; Dengke Yang; Jianguo Zhang; Chaoyang Zhu; Jiantao Sun; Zhongling Dou; Xiaofu Wang; Huiming Zhang; Wenhao Wang; Fei Xiao; Hepeng Cheng; Wenwei Lv; Bo Zhou; Xiaofan Zhang; Wuxue Li; Xinghua Zhao; Bin Hao; Changbao Xu
Journal:  Urolithiasis       Date:  2022-01-25       Impact factor: 3.436

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.